Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01011868 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 494
- Enrollment target
NCT01011868: Completed Phase 2 study, sponsored by Boehringer Ingelheim.
NCT01011868 is a Phase 2 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 494 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (271% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01011868, a Phase 2 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 494 participants
- Enrollment target
Study Summary
The objective of the current study is to investigate the efficacy, safety and tolerability of BI 10773 at two different doses compared to placebo during long term treatment (78 weeks) in combination with basal insulin in patients with type 2 diabetes mellitus with insufficient glycaemic control.
Primary Outcome
Change from baseline in Glycosylated haemoglobin A1c (HbA1c) after 18 weeks of treatment
Interventions
- DRUG BI 10773 placebo
- DRUG BI 10773 low dose
- DRUG BI 10773 high dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 494 participants |
| Start Date | 2009-11 |
| Phase | Phase 2 |
What the finished NCT01011868 record still lists
NCT01011868 is an interventional study that assigns participants to a tested intervention. The registered 494 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (271% higher).
The record links to 0 conditions, and to 3 interventions - of which BI 10773 placebo is the first listed.
NCT01011868 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01011868 about?
NCT01011868 is a clinical study titled "Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes". The objective of the current study is to investigate the efficacy, safety and tolerability of BI 10773 at two different doses compared to placebo during long term treatment (78 weeks) in combination with basal insulin in patients with type 2 diabetes mellitus with insufficient glycaemic control.
What is the current status of trial NCT01011868?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 494 participants. The study started on 2009-11.
What interventions are being tested in trial NCT01011868?
The interventions under investigation include: BI 10773 placebo (DRUG), BI 10773 low dose (DRUG), BI 10773 high dose (DRUG).
Who is sponsoring clinical trial NCT01011868?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01011868's enrollment target sits among peer trials
494 76th of 2000 higher than 1,925 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03127267 · 495 participants · Phase 3
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
- NCT06400472 · 495 participants · Phase 1
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
- NCT05283720 · 496 participants · Phase 2
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
- NCT06417775 · 496 participants · Phase 3
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia